These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [How do we need to maintain the iron status in dialyzed patients treated with erythropoesis stimulating agents]. Kes P; Basić-Jukići N; Jurić I Acta Med Croatica; 2009 Sep; 63 Suppl 1():54-61. PubMed ID: 20232552 [TBL] [Abstract][Full Text] [Related]
23. [Proceedings: Anemia and thrombopathies]. Blumberg A MMW Munch Med Wochenschr; 1974 May; 116(22):1105. PubMed ID: 4211576 [No Abstract] [Full Text] [Related]
24. Pathophysiology of renal anemia. Eckardt KU Clin Nephrol; 2000 Feb; 53(1 Suppl):S2-8. PubMed ID: 10746799 [TBL] [Abstract][Full Text] [Related]
25. Growth differentiation factor 15 in anaemia of chronic disease, iron deficiency anaemia and mixed type anaemia. Theurl I; Finkenstedt A; Schroll A; Nairz M; Sonnweber T; Bellmann-Weiler R; Theurl M; Seifert M; Wroblewski VJ; Murphy AT; Witcher D; Zoller H; Weiss G Br J Haematol; 2010 Feb; 148(3):449-55. PubMed ID: 19863534 [TBL] [Abstract][Full Text] [Related]
26. [Pathogenesis of anemia in chronic renal insufficiency]. Stefanovic S; Savin S; Pendic S; Ristic M; Jancic MS; Pavlovic-Kantera V; Banicevic B; Veljovic R; Glidzic L Bord Med; 1971 Mar; 4(3):821-2 passim. PubMed ID: 5089610 [No Abstract] [Full Text] [Related]
27. Hepcidin the link between inflammation and anemia in chronic renal failure. Atanasiu V; Manolescu B; Stoian I Rom J Intern Med; 2006; 44(1):25-33. PubMed ID: 17236285 [TBL] [Abstract][Full Text] [Related]
28. [Pathogenesis of nephrogenic anemia]. Riabov SI Klin Med (Mosk); 1981 Jul; 59(7):50-6. PubMed ID: 6168795 [No Abstract] [Full Text] [Related]
29. Hepcidin in anemia and inflammation in chronic kidney disease. Malyszko J; Mysliwiec M Kidney Blood Press Res; 2007; 30(1):15-30. PubMed ID: 17215586 [TBL] [Abstract][Full Text] [Related]
30. Iron therapy in chronic kidney disease: current controversies. Kovesdy CP; Kalantar-Zadeh K J Ren Care; 2009 Dec; 35 Suppl 2():14-24. PubMed ID: 19891681 [TBL] [Abstract][Full Text] [Related]
31. Inflammation and resistance to erythropoiesis-stimulating agents--what do we know and what needs to be clarified? Smrzova J; Balla J; Bárány P Nephrol Dial Transplant; 2005 Sep; 20 Suppl 8():viii2-7. PubMed ID: 16079326 [TBL] [Abstract][Full Text] [Related]
32. Peginesatide: a potential erythropoiesis stimulating agent for the treatment of anemia of chronic renal failure. Doss S; Schiller B Nephrol Nurs J; 2010; 37(6):617-26. PubMed ID: 21290916 [TBL] [Abstract][Full Text] [Related]
33. Correcting iron-restricted erythropoiesis and improving anemia in patients on hemodialysis: practical tips that can make a difference. Easom A Nephrol Nurs J; 2009; 36(5):529-37, 553. PubMed ID: 19856814 [TBL] [Abstract][Full Text] [Related]
34. [Erythropoesis-stimulating agents: past, present and future]. Kes P; Basić-Jukić N Acta Med Croatica; 2009 Sep; 63 Suppl 1():3-6. PubMed ID: 20235351 [TBL] [Abstract][Full Text] [Related]
35. Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure. van der Putten K; Braam B; Jie KE; Gaillard CA Nat Clin Pract Nephrol; 2008 Jan; 4(1):47-57. PubMed ID: 18094727 [TBL] [Abstract][Full Text] [Related]
36. Iron metabolism, iron deficiency, thrombocytosis, and the cardiorenal anemia syndrome. Besarab A; Hörl WH; Silverberg D Oncologist; 2009; 14 Suppl 1():22-33. PubMed ID: 19762514 [TBL] [Abstract][Full Text] [Related]
37. [Studies on the mechanism of anemia of chronic renal failure. I. Alterations in the levels of erythropoietic stimulating factor and of erythropoietic inhibiting factor in chronic renal failure]. Moriyama Y Nihon Ketsueki Gakkai Zasshi; 1970 Oct; 33(5):540-54. PubMed ID: 5535812 [No Abstract] [Full Text] [Related]
38. Anaemia, iron studies and erythropoietin in patients of chronic renal failure. Singh NP; Aggarwal L; Singh T; Anuradha S; Kohli R J Assoc Physicians India; 1999 Mar; 47(3):284-90. PubMed ID: 10999121 [TBL] [Abstract][Full Text] [Related]
39. [How do we optimally evaluate iron stores in dialyzed patients treated with erythropoiesis stimulating agent?]. Kessler M; Salignac S; Aimone-Gastin I Nephrol Ther; 2006 Sep; 2 Suppl 4():S261-5. PubMed ID: 17373268 [TBL] [Abstract][Full Text] [Related]
40. The challenges of using serum ferritin to guide i.v. iron treatment practices in patients on hemodialysis with anemia. Easom A Nephrol Nurs J; 2006; 33(5):543-51; quiz 552-3. PubMed ID: 17044438 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]